Welcome to







. , .pdf-, . . , . , , . e-mail. , , . , : (495) 730-63-51 e-mail: atm-press2012@yandex.ru



-




  

2015 / N 1

()
.. , ..

1. Sherman S., Lehman G.A. Sphincter of Oddi dysfunction: diagnosis and treatment // JOP. 2001. V. 2. P. 382400.
2. Kalloo A.N, Pasricha P.J. Therapy of sphincter of Oddi dysfunction // Gastrointest. Endosc. Clin. N. Am. 1996. V. 6. P. 117125.
3. .., .. // . . . 2009. 9. C. 5256.
4. .. : . .: , 2006. 448 .
5. Orford J.L., Dibos P.E., Soudry G. Sphincter of Oddi dysfunction: two case reports and a review of the literature // Clin. Nucl. Med. 2000. V. 25. P. 670675.
6. http//www.drugs.com
7. Takeda S., Aburada M. The choleretic mechanism of coumarin compounds and phenolic compounds // J. Pharmacobiodyn. 1980. V. 4. P. 724734.
8. Nadine N., Kuipers H.F., Frymoyer A.R. et al. 4Methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancer // Frontiers in Immunology. 2015. V. 6. P. 123.
9. Abate A., Dimartino V., Spina P. Hymecromone in the treatment of motor disorders of the bile ducts: a multicenter, doubleblind, placebocontrolled clinical study // Drugs Exp. Clin. Res. 2001. V. 27. P. 223231.
10. Camarri E, Marchettini G. Hymecromone in the treatment of symptoms following surgery of the bile ducts // Recenti Prog Med. 1988. V. 79. P. 198202.
11. Krawzak H.W., Heistermann H.P., Andrejewski K., Hohlbach G. Postprandial bileduct kinetics under the influence of 4methylumbelliferone (hymecromone) // Int J. Clin. Pharmacol. Ther. 1994. V. 33. P. 569572.
12. Quaranta S, Rossetti S, Camarri E. Doubleblind clinical study on hymecromone and placebo in motor disorders of the bile ducts after cholecystectomy // Clin. Ter. 1984. V. 108. P. 513517.
13. Trabucchi E., Baratti C., Centemero A. Controlled study of the effects of tiropramide on biliary dyskinesia // Pharmatherapeutica. 1986. V. 4. P. 541550.
14. Walter P., Seidel W. Studies on the effect of 4methylumbelliferon (Hymecromone) in patients following surgical revision of the biliary pathways // Chirurg. 1978. V. 50. P. 436440.
15. Hoffmann R.M., Schwarz G., Pohl C. Bile acidindependent effect of hymecromone on bile secretion and common bile duct motility // Dtsch. Med. Wochenschr. 2005. V. 130. P. 19381943.
16. Calabuig R., Castilla M., Pi F. Gallbladder dyskinesia in acalculous biliary colic // Rev. Esp. Enferm. Dig. 1996. V. 88. P. 770779.
17. Garrett E.R., Venitz J., Eberst K., Cerda J.J. Pharmacokinetics and bioavailabilities of hymecromone in human volunteers // iopharm. Drug. Dispos. 1993. V. 14. P. 1339.
18. Garrett E.R., Venitz J. Comparisons of detections, stabilities, and kinetics of degradation of hymecromone and its glucuronide and sulfate metabolites // J. Pharm. Sci. 1994. V. 83. P. 115116.
19. Mulder G.J., Brouwer S., Weitering J.G., Scholtens E. Glucuronidation and sulfation in the rat in vivo. The role of the liver and the intestine in the in vivo clearance of 4 methylumbelliferone. // Biochem. Pharmacol. 1985. V.34. p.13251329.
20. Rowland A., Mackenzie P.I., Miners J.O. Transportermediated uptake of UDPglucuronic acid by human liver microsomes: assay conditions, kinetics, and inhibition. // Drug Metab Dispos. 2015. V.43. P. 147153.
21. Uchaipichat V., Mackenzie P.I., Guo X.H. Human udpglucuronosyltransferases: isoform selectivity and kinetics of 4 methylumbelliferone and 1naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid // Drug Metab. Dispos. 2004. V. 32. P. 413423.
22. Rowland A., Miners J.O., Mackenzie P.I. The UDPglucuronosyltransferases: their role in drug metabolism and detoxification // Int. J. Bioch. Cell Biol. 2013. V.45. P. 11211132.
23. Guillemette C., Levesque E., Rouleau M. Pharmacogenomics of human uridine diphosphoglucuronosyltransferases and clinical implications // Clin. Pharmacol. Ther. 2014. V.96 p.324339.
24. Yamada T., Ohshita M., Ozawa K. et al. Effect of 4methylumbelliferone on the oxidative metabolism of liver mitochondria in jaundiced rats and its relationship of choleretic action. // Arzneimittelforschung. 1976. V. 26. P. 20402042.
25. Rilla K., Pasonen-Seppanen S., Rieppo J. The hyaluronan synthesis inhibitor 4methylumbelliferone prevents keratinocyte activation and epidermal hyperproliferationinduced by epidermal growth factor // J. Invest. Dermatol. 2004. V. 123. P. 708714.
26. Mahaffey C.L., Mummert M.E. Hyaluronan synthesis is required for IL2mediated T cell proliferation // J. Immunol. 2007. V. 179. P. 81918199.
27. GarciaVilas J.A., Quesada A.R., Medina M.A. 4Methylumbelliferone Inhibits Angiogenesis in Vitro and in Vivo // J. Agric. Food Chem. 2013. V. 61. P. 40634071.


  

[ N 1 | | ]